TOP TEN perturbations for Q969I6 (Homo sapiens)

Organism: Homo sapiens
Gene: Q969I6
Selected probe(set): 220786_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q969I6 (220786_s_at) across 5610 perturbations tested by GENEVESTIGATOR:

stem cell differentiation study 47 (BMP-2; 3d) / stem cell differentiation study 47 (0d)

Relative Expression (log2-ratio):5.2662153
Number of Samples:3 / 6
Experimental stem cell differentiation study 47 (BMP-2; 3d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 3 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 3 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, and 50 ng/ml BMP-2), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).
Control stem cell differentiation study 47 (0d)
Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).

glioma study 16 (LN-319) / normal astrocyte sample

Relative Expression (log2-ratio):5.2323513
Number of Samples:2 / 3
Experimental glioma study 16 (LN-319)
Human glioma cell line LN319 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

pancreatic islet study 3 (re-differentiated; PPRF; 2d) / normal pancreatic islet sample

Relative Expression (log2-ratio):-5.2262955
Number of Samples:2 / 7
Experimental pancreatic islet study 3 (re-differentiated; PPRF; 2d)
Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 2 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0ug/ml.
Control normal pancreatic islet sample
Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation.

pancreatic islet study 3 (re-differentiated; PPRF; 4d) / normal pancreatic islet sample

Relative Expression (log2-ratio):-5.1935997
Number of Samples:2 / 7
Experimental pancreatic islet study 3 (re-differentiated; PPRF; 4d)
Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 4 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0ug/ml.
Control normal pancreatic islet sample
Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation.

stem cell differentiation study 47 (BMP-2; 2d) / stem cell differentiation study 47 (0d)

Relative Expression (log2-ratio):5.165015
Number of Samples:3 / 6
Experimental stem cell differentiation study 47 (BMP-2; 2d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 2 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 2 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, and 50 ng/ml BMP-2), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).
Control stem cell differentiation study 47 (0d)
Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).

pancreatic islet study 3 (re-differentiated; PPRF; 6d) / normal pancreatic islet sample

Relative Expression (log2-ratio):-5.1470537
Number of Samples:2 / 7
Experimental pancreatic islet study 3 (re-differentiated; PPRF; 6d)
Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 6 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0 ug/ml.
Control normal pancreatic islet sample
Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation.

pancreatic islet study 3 (re-differentiated; PPRF; 8d) / normal pancreatic islet sample

Relative Expression (log2-ratio):-5.08817
Number of Samples:2 / 7
Experimental pancreatic islet study 3 (re-differentiated; PPRF; 8d)
Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 8 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0 ug/ml.
Control normal pancreatic islet sample
Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation.

stem cell differentiation study 47 (BMP-2; TGFb; 7d) / stem cell differentiation study 47 (0d)

Relative Expression (log2-ratio):4.996628
Number of Samples:3 / 6
Experimental stem cell differentiation study 47 (BMP-2; TGFb; 7d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and transforming growth factor beta (TGFb, 5 ng/ml). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).
Control stem cell differentiation study 47 (0d)
Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).

stem cell differentiation study 47 (BMP-2; TGFb; IBMX; 1d) / stem cell differentiation study 47 (0d)

Relative Expression (log2-ratio):4.928482
Number of Samples:3 / 6
Experimental stem cell differentiation study 47 (BMP-2; TGFb; IBMX; 1d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 24 hours in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml), transforming growth factor beta (TGFb, 5 ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 1 day in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).
Control stem cell differentiation study 47 (0d)
Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).

stem cell differentiation study 47 (BMP-2; TGFb; IBMX; 7d) / stem cell differentiation study 47 (0d)

Relative Expression (log2-ratio):4.914995
Number of Samples:3 / 6
Experimental stem cell differentiation study 47 (BMP-2; TGFb; IBMX; 7d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml), transforming growth factor beta (TGFb, 5 ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).
Control stem cell differentiation study 47 (0d)
Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).